Biogen, Inc. (BIIB) Lobbying Data
BIIB lobbying summary
Biogen, Inc. (BIIB) has reported $35.4M in federal lobbying spending across 162 Senate LDA filings since 2020. Its most frequent lobbying issues are Health Issues, Medicare/Medicaid, Pharmacy, Taxation. Lobbying firms used include Todd Strategy Group, Biogen, Jeffrey J. Kimbell & Associates, Inc..
Lobbying spending by year
| Year | Reported spend |
|---|---|
| 2026 | $3.9M |
| 2025 | $5.0M |
| 2024 | $4.9M |
| 2023 | $5.5M |
| 2022 | $5.9M |
| 2021 | $5.1M |
See insider trading for BIIB or the Lobbying Heavyweights strategy.
Source: Senate Lobbying Disclosure Act (LD-2) filings. The current year is partial.